Abstract A discussion of all the key issues in the use of human pluripotent stem cells for treating degenerative diseases or for replacing tissues lost from trauma. On the practical side, the topics range from the problems of deriving human embryonic stem cells and driving their differentiation along specific lineages, regulating their development into mature cells, and bringing stem cell therapy to clinical trials. Regulatory issues are addressed in discussions of the ethical debate surrounding the derivation of human embryonic stem cells and the current policies governing their use in the United States and abroad, including the rules and conditions regulating federal funding and questions of intellectual property.
From Book News, Inc. Eighteen contributions written by an international group of scientists, researchers, and physicians address the major issues in the use of human pluripotent stem cells for treating degenerative diseases or for replacing tissues lost from trauma. Topics range from the problems of deriving human embryonic stem cells and driving their differentiation along specific lineages, regulating their development into mature cells, and bringing stem cell therapy to clinical trials. Also covered are the criteria used by investigators in different fields to recognize mature phenotypes of specific tissues. Regulatory issues are addressed in discussions of the ethical debate surrounding the derivation of human embryonic stem cells and the current policies governing their use in the US and abroad.Copyright 2004 Book News, Inc., Portland, OR
Book Info National Institute of Health, Bethesda, MD. Addresses all the key issues in the use of human pluripotent stem cells for treating degenerative diseases or for replacing tissues lost from trauma. Provides a summary of the ethical debates surrounding stem cells and rules governing their use. For researchers.
Book Description A discussion of all the key issues in the use of human pluripotent stem cells for treating degenerative diseases or for replacing tissues lost from trauma. On the practical side, the topics range from the problems of deriving human embryonic stem cells and driving their differentiation along specific lineages, regulating their development into mature cells, and bringing stem cell therapy to clinical trials. Regulatory issues are addressed in discussions of the ethical debate surrounding the derivation of human embryonic stem cells and the current policies governing their use in the United States and abroad, including the rules and conditions regulating federal funding and questions of intellectual property.
|